The Nuffield Department of Clinical Medicine is part of the Medical Sciences Division. It hosts one of the largest groupings of Biomedical Researchers in the University Sector, and is also responsible for a significant part of the teaching of clinical medical students with the Oxford Medical School.
Digital Day aims to highlight the opportunities offered by using innovative Digital technologies to enhance and accelerate research. This event, held on the 9th December, aims to help researchers discover how digital technologies are transforming research across the University; see the benefits of digital research in and across different disciplines; speak to researchers using new tools to answer new research questions; explore possibilities for collaboration.
A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial to test whether it can protect people against the mosquito-borne disease. The trial was carried out in Oxford by researchers led by Professor Adrian Hill of the Jenner Institute at Oxford University.
NDM’s recently granted Athena SWAN Bronze Award was formally presented to the Department by Dame Julia Higgins FRS FREng, at a ceremony hosted by Imperial College, London on Nov 7th, 2013. Professors Peter Ratcliffe and Xin Lu were present to receive the award on behalf of NDM. Professor Ratcliffe stated the importance of retaining and developing diversity in the Department, “the inspiration, support, mentorship, career development, and ...
Dr Stuart Blacksell is a senior microbiologist at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand. His research interests include improving the diagnosis of tropical infections such as dengue and scrub typhus. He also evaluates the accuracy of commercial tests for tropical illnesses. Dr Blacksell has a strong interest in promoting biosafety in Asia.
Putting drug discovery back on target
Interview with Chas Bountra and Peter Ratcliffe.
'The world urgently needs new medicines for many diseases', says Professor Chas Bountra, 'the fundamental bottleneck is our ability to identify new targets for drug discovery.' Professor Peter Ratcliffe is of exactly the same mind: 'In starting drug development you need to start in the right place. We need to have the right molecular target.' The new Target Discovery Institute aims to validate targets for drug discovery.
Read the University Science Blog